Lexeo Therapeutics, Inc. filed a Form S-3 shelf registration statement with the U.S. Securities and Exchange Commission on October 29, 2026, seeking to register up to $300,000,000 in aggregate securities offerings.

Key Highlights

  • Total shelf size: Up to $300,000,000 in aggregate securities, including common stock, preferred stock, debt securities, warrants, subscription rights, purchase contracts, and units.
  • Unsold securities carried forward: $135,387,220.20 of unsold securities from the prior registration statement (File No. 333-283781) are being carried forward under Rule 415(a)(6).
  • Prior registration statement: The earlier Form S-3 (File No. 333-283781) was originally filed December 13, 2024, and declared effective December 19, 2024.
  • Filing fee carried forward: The aggregate filing fee paid in connection with the unsold securities was $20,727.78, which is being carried forward to this registration statement.
  • Stock price at filing: The last quoted sale price of common stock on October 28, 2026, as reported on Nasdaq, was $3.13 per share.
  • Company classifications: Lexeo Therapeutics is classified as a non-accelerated filer, smaller reporting company, and emerging growth company under applicable SEC definitions.

Lexeo Therapeutics Registers New $300 Million Shelf, Carries Forward Unsold Prior Offering

Lexeo Therapeutics, Inc. (NASDAQ:LXEO), headquartered at 345 Park Avenue South, Floor 6, New York, New York 10010, filed a preliminary Form S-3 shelf registration statement on October 29, 2026. According to the filing, the company may sell up to $300,000,000 in aggregate securities from time to time, in one or more offerings, with amounts, prices, and terms to be determined at the time of each offering. Specific terms will be provided in prospectus supplements to be filed separately.

The filing discloses that $135,387,220.20 of unsold securities from a prior registration statement (File No. 333-283781) are being carried forward to this new registration statement pursuant to Rule 415(a)(6). That prior registration statement was originally filed on December 13, 2024, and declared effective on December 19, 2024. The filing states that the offering of unsold securities under the prior registration statement will be deemed terminated as of the date of effectiveness of the new registration statement. If any unsold securities are sold under the prior registration statement between the initial filing of this new statement and its effective date, the company stated it will file a pre-effective amendment reducing the number of unsold securities carried forward.

The securities covered by the shelf registration include common stock, preferred stock, debt securities, warrants, subscription rights, purchase contracts, and units. According to the filing, securities may be sold directly to investors, through agents, or through underwriters and dealers, with compensation arrangements to be described in applicable prospectus supplements. The company's common stock is listed on the Nasdaq Global Market under the symbol "LXEO," and the last quoted sale price as reported on Nasdaq on October 28, 2026, was $3.13 per share. The filing notes that investing in the company's securities "involves a high degree of risk" and directs investors to the Risk Factors section beginning on page 6 of the prospectus.

What Was Disclosed

Lexeo Therapeutics filed a Form S-3 shelf registration on October 29, 2026, to register up to $300,000,000 in various securities, carrying forward $135,387,220.20 in unsold securities from a prior effective registration statement under Rule 415(a)(6).